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We describe a novel TCR-transgenic mouse line, TCR7, where MHC class II-restricted,
CD4+ T cells are specific for the subdominant H-2b epitope (HEL74–88) of hen egg
lysozyme (HEL), and displayed an increased frequency in the thymus and in peripheral
lymphoid compartments over that seen in non-transgenic littermate controls. CD4+
T cells responded vigorously to HEL or HEL74–88 epitope presented on APC and could
develop into Th1 or Th2 cells under appropriate conditions. Adoptive transfer of TCR7
Ly5.1 Tcells into Ly5.2 rat insulin promoter (RIP)-HEL transgenic recipient hosts did not
lead to expansion of these cells or result in islet infiltration, although these TCR7 cells
could expand upon transfer into mice expressing high levels of HEL in the serum. Islet
cell infiltration only occurred when the TCR7 cells had been polarized to either a Th1 or
Th2 phenotype prior to transfer, which led to insulitis. Progression from insulitis to
autoimmune diabetes only occurred in these recipients when Th1 but not Th2 TCR7
cells were transferred and CTLA-4 signalingwas simultaneously blocked. These findings
show that regulatory pathways such as CTLA-4 can hold in check already differentiated
autoreactive effector Th1 cells, to inhibit the transition from tolerance to autoimmune
diabetes.
See accompanying commentary at http://dx.doi.org/10.1002/eji.200636591
Introduction
Autoimmune diseases that target specific organs such as
the pancreatic islets, thyroid and other organs of the
endocrine or nervous systems have been shown to
cluster together in individuals where there is a large
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inherited component for susceptibility which has been
attributed genetically to MHC and non-MHC chromo-
somal regions [1]. The nature of the defects which lead
to such diseases is as yet unclear. Self-reactive Tcells can
be readily detected in the circulation and peripheral
tissue of animals and humans and most do not develop
any apparent autoimmune disease.
Induction of clonal deletion and clonal anergy are
mechanisms for arresting self-reactive T cells in the
thymus or in the peripheral immune system [2, 3]. These
mechanisms require a critical threshold of antigen/MHC
and TCR affinity to be triggered, which in some cases
cannot be achieved since the low amounts of antigen in
the thymus or the periphery are not sufficient to trigger
autoreactive T cells of low TCR avidity [2–10].
Heterogeneity of autoreactive T cells has hampered
the ability to relate this possible cause of autoimmunity
to function. In addition to such mechanisms of deletion
and anergy there have been many reports suggesting
that organ-specific autoimmune diseases may occur
either by excessive stimulation of autoreactive T cells
[11–13], or inadequate dampening of their responsive-
ness by defects or decreases in Th2 cells [14], regulatory
T cells [12, 15, 16] or NKT cells [17, 18].
A high self-reactive Tcell frequency [19], appropriate
costimulation by islet b cells [20], a Th1 cytokine profile
[8, 21, 22] and high TCR-MHC affinity [9] have been
observed to potentiate diabetes in otherwise resistant
models, or to accelerate diabetes in neonatal diabetes-
prone mice. Moreover, there is evidence that the onset of
diabetes is controlled by a regulatory population [16, 23,
24]. Blockade of cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4) [25, 26] has also been shown to
provoke rapid diabetes in certain model systems on a
NOD background [27, 28] in addition to exacerbating
other autoimmune disorders [29, 30]. In addition, it has
also been suggested that blockade of CTLA-4 signaling
may interfere with the function of naturally occurring
regulatory T cells to suppress inflammation [31, 32].
More recently, cooperative roles of CTLA-4 and
regulatory T cells have been proposed in tolerance for
an islet antigen [33]. It is likely, that a combination of
genetic defects in the threshold of reactivities of
autoreactive T cells, their regulation and possibly
environmental factors such as viral infections may
ultimately result in such autoimmune pathologies.
Different models of TCR transgenics have been
described thatmake use of islet-reactive Tcell clones that
could be isolated from autoimmune mice and therefore
fell under the threshold of thymic negative selection, but
thus far the islet antigens have been unidentified [21, 34,
35]. Alternatively, islet-reactive CD4+ Tcells with awell-
defined TCR recognizing an antigen with known
specificity and avidity may be used, if the antigen is
expressed in the pancreatic islet b cells [2, 3, 10, 35].
To study the immunoregulatory checkpoints that
inhibit the development of diabetes [36], we tracked the
fate of CD4+ T cells, at different stages of activation or
differentiation, in a model where TCR specific for an
islet-expressed neo-antigen and the islet antigen were
kept constant. Transfer of these islet antigen-specific
T cells into recipient mice expressing the neo-antigen
thus enabled the study of the immunoregulatory circuits
in place in the periphery to check first entry into the
pancreatic islets and second destruction of the islet
b cells, and subsequent diabetes.
Results and discussion
Generation and characterization of hen egg
lysozyme-specific TCR transgenics: TCR7 mice
A novel TCR-transgenic mouse line was produced, by
making DNA constructs (Fig. 1A) carrying functionally
rearranged anti-hen egg lysozyme (HEL) TCR Va11 and
Vb3 chain genes obtained from a HEL-specific T cell
hybridoma, which recognizes a subdominant but not
cryptic peptide of HEL [36]. Cell surface expression of
the transgenic TCR was confirmed by transfection of the
a and b chain constructs into a TCR-negative T cell
hybridoma (58a–b–), [37] and flow cytometric analysis
for Vb3 (Fig. 1A), which requires the co-expression of Va
(in this case Va11). Two transgenic founder mice
carrying the anti-HEL TCR a and b chain genes were
produced using fertilized eggs from inbred C57BL/6J
mice. T cell development appeared the same in the two
lines, and one line, TCR7, wasmaintained on this genetic
background and used in subsequent studies.
Thymic CD4+ Tcell development in TCR7 transgenic
mice displayed strong positive selection with a fivefold
rise in the frequency of CD4 single-positive thymocytes
over that seen in non-transgenic littermate controls
(Fig. 1B). Moreover, the frequency of CD4+ cells
expressing Vb3 was also elevated in the peripheral
lymphoid compartments of TCR7 transgenic mice as
compared with non-transgenic controls and >80% of
the CD4+ splenic or inguinal lymph node T cells
expressed Vb3 (Fig. 1B).
Spleen cells, or purified CD4+ T cells, from TCR7
transgenic mice stimulated in vitro with various
concentrations of HEL protein or the I-Ab-restricted
HEL74–88 epitope for which the transgenic TCR is specific
[36], made a vigorous response to HEL, which was
absent in the non-transgenic control cells (Fig. 1C). In
addition, naive CD4+ sorted TCR7 cells developed
normally to either a Th1 phenotype secreting IFN-cwith
little IL-4, or to a Th2 phenotype secreting IL-4 with little
IFN-c when stimulated with HEL74–88 presented by
irradiated splenic APC under the appropriate conditions
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of IL-12 and/or anti-IL-4 for Th1, or IL-4 and/or
anti-IL-12 for Th2 development (Fig. 1D).
Fate of TCR7 cells after adoptive transfer to
recipient mice expressing HEL
As reported with a distinct HEL-specific TCR-transgenic
(H-2k-restricted) mouse line [10], whenTCR7mice were
crossed with rat insulin promoter (RIP)-HEL mice that
express membrane HEL on pancreatic b cells (RIP-HEL),
autoreactive HEL-specific TCR7 Tcells were able to leave
the thymus and some of the cells migrated to the
pancreas and caused insulitis but not diabetes (data not
shown). To study further the checkpoints required to
prevent such autoreactive CD4+ T cells from first
migrating to the pancreas, and then inhibiting them
from inducing diabetes, transfer experiments were
performed using Ly5.1+ HEL-specific TCR-transgenic
cells and Ly5.2+ recipients of the following types: RIP-
HEL (express membrane HEL on pancreatic b cells, and
Figure 1.Generation and characterization of TCR7mice. (A) The anti-HELTCR a chain constructwasmade by insertion of the anti-
HEL TCR a chain VJ region DNA fragment obtained from the BO4H9.1 T cell hybridoma [36] and neo gene into the pVCaK TCR
a chain construct [45] as described in Materials and methods.The FACS histogram shows 58a–b– cells [37] stained with an anti-Vb3
antibody (the transgene b chain specificity) and only observed when co-transfected with the anti-HEL TCR a and b chain
constructs. Equivalent staining was also obtained with an anti-CD3 antibody, indicating that both the a and b chain genes were
expressed on the cell surface. (B) CD4/CD8 profiles of thymi from non-transgenic (Non-Tg) littermate (left) and TCR7 transgenic
(TCR7-Tg) mice (right) are shown in the upper row of panels with the corresponding CD4/Vb3 expression for the spleen and
inguinal lymph node displayed below. The percentage of cells present in each quadrant is also indicated in the top right of the
individual plots. (C) T cell proliferation was measured by [3H]thymidine incorporation for either 1106 whole spleen cells from
non-transgenic (Non-Tg, open symbols) or TCR7 transgenic (TCR7-Tg, closed symbols)mice stimulatedwith the indicated doses of
HEL protein (Lysozyme) or HEL74–88 peptide, or for the indicated number of CD4 purified spleen cells from these mice stimulated
with 1106 irradiated splenic APC in the presence of 1.1 lM HEL74–88 peptide (triplicate cultures). (D) Naive (Mel-14bright) CD4+
spleen cells sorted from TCR7 transgenic mice were set up in primary cultures with HEL74–88 peptide and APC (irradiated spleen
cells) for 7 days in the absence of polarizing cytokines (None) or in the presence of either Th2- or Th1-inducing conditions as
described inMaterials andmethods. Cellswere then restimulatedwithHEL74–88 peptide + APC for 48 h, and IL-4 and IFN-c content of
the supernatants determined by ELISA (limit of sensitivity: IFN-c, <125 pg.mL; IL-4, <100 pg/mL). Results are representative of
three experiments and data are represented as the mean  SD of triplicate cultures.
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have 1.2 ng/mL HEL in the serum); M-HEL, (express
HEL on most cell types under control of the class I
promoter and have 150–200 ng/mL HEL in the serum);
solHEL (express soluble HEL in the liver and have
10–20 ng/mL in the serum) and non-transgenic mice as
controls.
TCR7 (Ly5.1) donor cell frequency in the spleen of
non-transgenic, solHEL or RIP-HEL recipients dwindled
rapidly over the 5 days after transfer, to almost
undetectable levels due to insufficient activation
(Fig. 2A). By contrast, donor TCR7 cells expanded
and persisted and their frequency remained elevated in
identical transfers to M-HEL recipient mice (Fig. 2A).
Expression of HEL under the class I promoter has
previously been demonstrated to result in enhanced
processing and thus reactivity to HEL [10], suggesting
that the cells are failing to be maintained in the
periphery of non-transgenic, solHEL or RIP-HEL mice
when they have to compete with a normal T cell
compartment, whereas they get sufficient engagement
to promote survival in M-HEL mice.
TCR7 CD4+Ly5.1+ cells were detected in the spleen
of M-HEL mice at an approximate frequency of 3–6% of
live lymphocytes (Fig. 2A and data not shown) and
exhibited evidence of activation, with modulation of
CD44hi, CD45RBlo and Mel-14lo seen for at least
150 days after transfer (data not shown). In addition,
10 days after transfer, the HEL-specific proliferative
Figure 2. Long-term expansion of TCR7 T cells is seen only after adoptive transfer to M-HEL, but not to solHEL, RIP-HEL or non-
transgenic recipients. (A) Recipient spleens were harvested from 6 h to 10 days after the indicated Ly5.2 recipient mice were
adoptively transferredwith 40106 TCR7 Ly5.1 cells. Flow cytometric analysis for CD4+ Ly5.1+ cellswas used to detect the presence
of donor T cells within recipient spleens. Their frequency was calculated as the percentage of CD4+Ly5.1+ cells within a live
lymphocyte gate of the recipient spleen and the numbers shown are representative of five mice per group and at least three
identical experiments. (B) Proliferative responses are shown for spleen cells from the indicated recipient mice after cultures
identical to those described in Fig. 1D. Also shown are the percentages of CD4+Vb3+ T cells expressed as a fraction of the live
lymphocytes presentwithin each population used for the proliferation assays. Similar resultswere found in at least three identical
experiments.
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capacity of CD4-enriched spleen cells from M-HEL
transgenic recipients was strongly enhanced over that of
untransferred non-transgenic controls, while there was
no augmented proliferation in non-transgenic, solHEL
or RIP-HEL groups that had received TCR7 cells
(Fig. 2B). The capacity of these transferred TCR7
CD4+ T cells to respond to HEL in vitro paralleled the
frequency of CD4+Vb3+ TCR7 cells present in the
cultures and demonstrated their ability to respond to
HEL.
The autoreactive TCR7 cells transferred to M-HEL
recipients induced enhanced levels of IgG autoantibo-
dies to double-stranded DNA in their sera [38], which
was not seen in either non-transgenic, solHEL or RIP-
HEL transgenic recipients (data not shown). Although
this is consistent with a systemic lupus erythematosus
disorder [39], these mice did not develop raised
proteinurea, and only a mild chronic ascending
pyelonephritis was seen in their kidney (data not
shown), rather than the glomerulonephritis character-
istic of systemic lupus erythematosus. Analysis of the
pancreas of RIP-HEL transgenic recipients of HEL-
specific TCR7 cells showed no infiltration into the
pancreas over a 4-month period after transfer and these
mice were normoglycemic (data not shown). Given that
a small frequency of CD4+Vb3+ cells remained in these
mice and could be expanded upon immunization
without inducing diabetes (data not shown), we
reasoned that the donor TCR7 cells were clonally
ignorant of the pancreas-restricted neo-self antigen in
RIP-HEL mice. Furthermore, transfer into M-HEL mice
did not result in any organ-specific disease despite great
expansion in the periphery of TCR7 CD4+ T cells after
transfer.
Blockade of CTLA-4 signaling allows Th1 but not
Th2 cells to cause diabetes
In other systems of diabetes, failure of activation of
autoreactive T cells could be overcome either by
peripheral immunization or infection [4, 40] or by
transfer of differentiated Th1 cells [21, 22, 41] into
neonatal diabetes-prone mice, suggesting that induction
of pathology and escape from peripheral tolerance
mechanisms required appropriate T cell activation/
differentiation and possibly the appropriately suscep-
tible genetic background [4, 40]. We attempted to
provoke autoimmune infiltration of the islets by
activating the TCR7 cells prior to transferring to the
RIP-HEL mice. Only when TCR7 cells were stimulated
with HEL and polarized to a Th1 phenotype in the
presence of IL-12 and anti-IL-4, were the transferred
cells capable of inducing a moderate islet infiltrate
(Fig. 3A). This was reminiscent of the pathology
typically seen in autoimmune diabetes, with a presence
of lymphocytes, plasma cells and rare neutrophils. In
contrast, transfer of Th2 TCR7 cells, induced by
stimulating with HEL74–88 and APC in the presence of
IL-4 and anti-IL-12, induced a peri-islet infiltration,
which was comprised primarily of eosinophils with
fewer lymphocytes, plasma cells and rare neutrophils
(Fig. 3B). No insulitis was observed in RIP-HEL
recipients of TCR7 cells primed in non-polarizing
conditions using cross-linked anti-CD3 plus anti-CD28
(data not shown).
Interestingly, there was never a prolonged elevation
of blood glucose levels under any of these circumstances
(Fig. 3C) and the insulitis observed after transfer of
either Th1 or Th2 TCR7 cells appeared to be held in
check throughout an 8-month monitoring period, in
contrast to reports in other models where Th1 cells
specific for islet antigens induced diabetes [8, 21]. This
difference could be due to the genetic background of the
TCR7 mouse (C57BL/6 versus those used in other
studies) [8, 21]. Alternatively it is possible that since the
TCR7 mice respond to a subdominant peptide of
HEL74–88 (Fig. 1C) the ability of islet-specific Th1 cells
to further infiltrate the islets and cause diabetes can still
be held in check by additional peripheral regulatory
mechanisms [8, 21, 42].
We thus assessed whether or not treatment with anti-
CTLA-4 mAb would provoke disease as it had in other
systems of diabetes on a NOD background [28, 43].
Indeed RIP-HEL mice developed diabetes with 100%
incidence by 50 days after transfer of Th1 TCR7 cells
when co-administered with anti-CTLA-4mAb at the time
of transfer (Fig. 3C). In contrast, anti-CTLA-4 mAb
treatment did not induce diabetes in RIP-HEL mice
either untransferred (data not shown) or after their
receipt of Th2 TCR7 cells (Fig. 3C). Interestingly, anti-
CTLA-4 treatment made no noticeable difference to
either the extent of infiltration or the cell types present
in RIP-HEL recipients of either Th1 or Th2 TCR7 cells
(Fig. 3D, E). Therefore, the mechanism by which anti-
CTLA-4 mAb provokes diabetes in this system appears to
segregate with the Th1 TCR7 cell subset and has no
detectable effect on the autoreactive potential of Th2
TCR7 cells, probably as a result that Th1 cytokine
production can provoke autoimmune pathologies,
whereas in contrast Th2 cells have been suggested to
inhibit them [42].
These studies suggest that the HEL-specific Th1 cells,
although able to infiltrate the pancreas, cannot over-
come the threshold of immune regulation to evoke
disease. The inhibition of CTLA-4 signaling may
interrupt the activation or function of regulatory
T cells, as previously suggested [31, 32], or alternatively
remove intrinsic negative signaling in the Th1 cell by
CTLA-4 [26, 33] per se, thus lowering its threshold of
activation. Our studies show that even fully differen-
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tiated Th1 cells that have migrated to the pancreas and
can cause insulitis are still subject to immune regulatory
mechanisms.
Concluding remarks
We describe here a novel TCR-transgenic line, TCR7,
where MHC class II-restricted, CD4+ T cells are specific
for the subdominant H-2b epitope (HEL74–88) of HEL.
Adoptive transfer of TCR7 (Ly5.1) T cells into RIP-HEL
(Ly5.2) recipient hosts did neither lead to expansion of
these cells nor result in islet infiltration, although these
TCR7 cells could expand upon transfer into mice
expressing high levels of HEL in the serum. Islet cell
infiltration only occurred when the TCR7 cells had been
polarized to either a Th1 or Th2 phenotype prior to
transfer, which led to insulitis. However, progression
from insulitis to autoimmune diabetes only occurred in
these recipients when Th1 but not Th2 TCR7 cells were
transferred and CTLA-4 signaling was simultaneously
blocked. These findings show that even already
differentiated autoreactive effector Th1 cells that have
migrated into the pancreas fail to induce diabetes and
are still held in check by powerful regulatory elements.
These regulatory mechanisms are revealed using
blocking anti-CTLA-4 antibodies which may be operat-
ing via regulatory T cells or directly on effector cells, to
inhibit the transition from tolerance to autoimmune
diabetes. These findings are in keeping with previous
reports that variations in the CTLA-4 molecule are
associated with susceptibility to type I diabetes in
humans and in the NOD mouse model for this disease
[44], and provide a new model for further study of the
molecular and cellular pathways involved in type I
diabetes.
Figure 3. Requirements for diabetes in RIP-HELmice: Transfer of Th1 TCR7 cells results in insulitis that can induce diabetes in the
absence of CTLA-4 signaling. Th1- and Th2-polarized TCR7 spleen cells were prepared and 9106 CD4+Vb3+ cells were transferred
to recipients. Representative H&E-stained sections are shown for pancreata removed from RIP-HEL recipients 50 days after
transferring either (A) Th1- or (B) Th2-polarized TCR7 cells. (C) RIP-HEL mice were injected i.p. with 200 lg of either anti-CTLA-4
mAb or isotype-matched controlmAb 1 day prior to and on days 3 and 5 after transfer of Th1 or Th2 TCR7 cells as described above.
Diabetes developmentwasmonitored by regular blood glucosemeasurements and the incidence of disease is shown for fivemice
per group from two identical experiments. H&E-stained pancreata were also prepared where a representative section from anti-
CTLA-4-treated RIP-HEL recipients of either (D) Th1- or (E) Th2-polarized TCR7 cells is shown. Pancreata of isotype control mAb-
treated RIP-HEL recipients of Th1- or Th2-polarized TCR7 cells were identical to those shown in (A, B). For all sections, the upper
panel shows40 original magnification and the lower panel shows160 original magnification. The presence of lymphocytes (>)
predominates in (A, D), while eosinophils (/) comprise the majority of cells present in (B, E).
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Materials and methods
Generation of TCRab-transgenic mice
HEL-specific TCR-transgenic mice were made using gene
constructs encoding functionally rearranged a and b chain
TCR genes obtained from the Tcell hybridoma BO4H9.1, which
recognizes HEL74–88 peptide in the context of I-A
b [36]. The
HEL TCR a chain gene construct was made by insertion into
the plasmid pBS a 4-kb EcoRI-EcoRV genomic fragment
containing the functionally rearranged VJ region of the TCR
a chain gene cloned from BO4H9.1 cells (a kind gift from
N. Shastri). A 2.9-kb fragment containing the anti-HEL VJ
region was then removed by digestion with BamHI and
subcloned into BglI-BamHI-digested pUG-1 into which the
1.6-kb neomycin (neo) gene had been inserted (a gift from
C. Somoza). From this, the neo and anti-HELVJ genes (4.5 kb)
were removed by digestion with XhoI and BamHI and inserted
into a TCR gene construct (pVCaK; a kind gift from A. Winoto
[45]) containing the a chain constant region, enhancer, and
locus control region. To do this, the plasmid pVCaK was first
digestedwith SalI and partially digested with BamHI to remove
the existing VJ region, leaving a 21.8-kb linearized vector and
control regions. The XhoI-BamHI fragment containing the anti-
HEL VJ region and neo gene was then inserted, giving the
complete anti-HEL TCR a chain gene construct.
The anti-HEL TCR b chain gene construct was made by
inserting into pBS a 4.9-kb EcoRI-BamHI DNA fragment
containing the TCR b chain enhancer (obtained from a
modified b shuttle vector (a kind gift from M. Davis [46]).
This was done by treating the EcoRI-BamHI fragment with
Klenow and EcoRI linkers added and cloning into EcoRI-
digested pBS. The resulting plasmid was linearized by partial
digestion with HindIII and into this was inserted a 9-kb HindIII
genomic DNA fragment encoding the functionally rearranged
anti-HEL TCR b chain VDJ region and downstream constant
regionwhich had been cloned from the BO4H9.1 hybridoma (a
gift from N. Shastri). Positioning the VDJ region upstream of
the enhancer region gave the complete anti-HEL TCR b chain
gene construct.
Stable co-transfection of the anti-HEL TCR a and b chain
constructs into 58a–b– cells (a T cell hybridoma lacking TCR
expression; a gift of B. Malissen) followed linearization of the
a chain by PvuI digestion, and of the b chain by ClaI digestion,
electroporation and G418 (Gibco BRL/Life Technologies,
Gaithersburg, MD) selection (using 500 lg/mL G418) as
described for Sp2/0 cells [47]. Representative transfectants
were stained with fluorescinated anti-Vb3 antibody (the
transgene specificity; obtained from Pharmingen, San Diego,
CA) and analyzed on the FACScan (Becton Dickinson, San
Jose, CA).
For oocyte microinjection the a chain gene construct was
removed from vector sequences by digestion with ClaI, and the
b chain removed by digestion with SalI-SacII. The DNA was
purified by cesium chloride centrifugation prior to microinjec-
tion into C57BL/6J eggs (Jackson Research Laboratories, Bar
Harbor, ME). In this way, two founder mice were obtained,
TCR7 and TCR9. TCR7 was used in the experiments described
here, and maintained by crossing to C57BL/6J mice (Jackson
Laboratories).
Mice
Female C57BL/6 and C57BL/6.Ly5.1 mice were purchased
from Jackson Research Laboratories. The generation of M-HEL
(KLK-4), solHEL (ML-5) and RIP-HEL (ILK-3) transgenic mice
(all on a C57BL/6 background) has been previously described
[2, 3, 10, 35, 48, 49] and colonies of each line were maintained
by breeding with C57BL/6 mice. These mice were a kind gift
from Dr. C. C. Goodnow. In order to track HEL-specific TCR-
transgenic T cells (TCR7), TCR7.Ly5.1 were obtained by
breeding TCR7 mice with C57BL/6.Ly5.1 mice, while
TCR7.Ly5.1RAG2–/– were obtained by crossing TCR7.Ly5.1
mice with RAG2–/–Ly.5.1 mice (Jackson Research Labora-
tories) and then intercrossing TCR7.Ly5.1RAG+/–.
All transgenic animals were genotyped by polymerase chain
reaction on ear punch DNA [50] using primer sequences kindly
provided by Dr. C. C. Goodnow for each HEL-transgenic line
[10, 35], or forward endogenous 50-GTCCTCCGTGTCCATATT-
30, forward transgenic 50-ATCTGGTGAAAGGGCAAGGA-30 and
reverse 50-CAAGGAGGAACCATGAGCA-30 primer sequences
for TCR7 mice. In all cases, 35 cycles of 94C for 15 s, 60C for
30 s and 72C for 1 min were performed before polymerase
chain reactions were separated on 2% agarose gels and
visualized by ethidium bromide staining under UV illumina-
tion. TCR7.Ly5.1RAG2–/– mice were additionally screened by
FACS analysis to confirm that they lacked lymphocytes other
than those of a CD4+Vb3+ profile. All mice were housed under
specific pathogen-free conditions and were used at the age of
6–8 wk.
Media, antigens, antibodies, cytokines and reagents
Cell culture medium was RPMI 1640 medium (Bio-Whittaker,
Walkersville, MA) supplemented with 10% FCS (Hyclone
Laboratories, Logan, UT), 1 mM L-glutamine, 10 mM Hepes,
100 U/mL penicillin, 100 lg/mL streptomycin, 1 mM sodium
pyruvate and 0.05 mM b-2-mercaptoethanol (all Gibco BRL,
Grand Island, NY). Unsupplemented Hanks' medium (Gibco
BRL) was used for all adoptive cell transfers. HEL protein was
obtained from Sigma, while the antigenic peptide (HEL74–88)
from HEL was synthesized on an Applied Biosystems
model 430 peptide synthesizer (Foster City, CA). Recombinant
mouse cytokines used were IL-2, IL-4 (both DNAX) and IL-12
(Pharmingen, San Diego, CA). Anti-IL-12 (C17.8.20 [51]),
anti-IL-4 (11B11 [52]) and anti-CTLA-4 (UC10–9H10 [53])
were used with an isotype-matched control mAb when
appropriate.
CD4+ T cell purification and CD4+, Th1 and Th2 cell
culture
CD4+ T cells were enriched from spleen cell preparations by
negative selection and purified further using a FACStar Plus
flow cytometer (Becton Dickinson, Mountain View, CA) to
achieve >99% CD4+Mel-14+ T cells as previously described
[54]. Whole or CD4-enriched spleen cells were incubated for
48 h at 37C in 96-well plates (106 or 5105 cells per 200 lL
per well, respectively), with either titrated amounts of HEL
protein or HEL74–88 peptide and red blood cell (RBC)-lysed
C57BL/6 spleen cells (1106/well, 3000 rad) as APC. Super-
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natants were harvested after 48 h of culture and stored at
–80C until analyzed for cytokine content, or cell cultures were
pulsed for a further 20 h with 1 lCi [3H]thymidine (Amer-
sham) to measure proliferative responses.
Th1 and Th2 cell differentiation was achieved in culture
using 1.1 lM HEL74–88 and RBC-lysed C57BL/6 spleen
cells (1106/well, 3000 rad) as APC with either IL-12
(10 ng/mL)  anti-IL-4 (10 lg/mL) for Th1 conditions, or
IL-4 (10 ng/mL)  anti-IL-12 (10 lg/mL) for Th2 conditions
as previously described [54]. Supernatants were collected after
secondary stimulation (as in [54]) at 48 h and stored at –80C
until analyzed for IL-4 (Th2) and IFN-c (Th1), which were
detected using a two-site sandwich ELISA as previously
described [54].
Adoptive transfer of mice
Approximately 40106 RBC-lysed spleen cells (containing
approximately 4106–9106 CD4+Vb3+ T cells) from
TCR7.Ly5.1 mice were transferred intravenously in 0.2 mL
Hanks' medium to recipient mice (Ly5.2). Where indicated, the
donor population was first polarized to a Th1 or Th2
phenotype as described above and previously [54]. Approxi-
mately 9106 CD4+Vb3+ Tcells per recipient were transferred
into C57BL/6 recipient mice. When indicated, the recipients
were administered intraperitoneally (i.p.) several times
(weekly) with either 200 lg per injection of anti-CTLA-4 or
isotype-matched irrelevant hamster control antibody prepared
in PBS.
Flow cytometry
Single-cell suspensions of thymus, spleen or lymph node cells
were depleted of contaminating RBC and stained as previously
described [54] with various combinations of the following rat
anti-mouse conjugated antibodies: FITC-conjugated Ly5.1; PE-
conjugated Vb3, Mel-14, CD45RB or CD69; Cy-Chrome-
conjugated CD4 or CD8; allophycocyanin-conjugated CD4;
or biotin-conjugated Vb3 followed by streptavidin-allophyco-
cyanin at pre-determined optimal doses (most antibodies from
Pharmingen; secondary antibody from Caltag, Burlingame,
CA). Viable cells (50 000 per sample), gated for lymphocytes
by a combination of forward and side scatter, were analyzed on
a FACSCaliberTM (Becton Dickinson) using CellQuestTM soft-
ware.
Histology
Hematoxylin and eosin (H&E) staining of 4-lm sections from
buffered formalin-fixed paraffin-embedded pancreata was
performed as described [55]. Multiple sections (at least 30)
of pancreas from each animal were analyzed for insulitis as
described [55]. Islets were judged to be free of infiltrates,
suffering from peri-insulitis (if the infiltrates were limited to
the surrounding ducts and vasculature and islet architecture
appeared normal), suffering from moderate insulitis (if less
than 50% of the islet was infiltrated), or suffering from severe
insulitis (if 50% or greater of the islet was infiltrated and islet
architecture was severely disrupted).
Assessment of diabetes
Diabetes was assessed every 10 days by measurement of blood
glucose using Accu-Chek AdvantageJ test strips and blood
glucose monitor (Roche Diagnostics Corporation). Animals
were considered diabetic after two sequential measurements
above 250 mg/dL and this was confirmed by urine glucose
measurements using dip sticks (Bayer Corporation, Elkhart,
IN). Onset of diabetes was dated from the first of the sequential
diabetic measurements.
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